Staff Profile: Pablo Cure

Pablo Cure, M.D., M.P.H.

Program Director

Division of Clinical Innovation
Clinical and Translational Science Awards Program Branch
Digital & Mobile Technologies Section

National Center for Advancing Translational Sciences

National Institutes of Health

Email Pablo Cure


Pablo Cure is a program director in the Digital & Mobile Technologies Section of the Clinical and Translational Science Awards (CTSA) Program Branch within NCATS’ Division of Clinical Innovation, where he manages a portfolio of CTSA Program grants. Prior to joining NCATS in November 2017, Cure was a health scientist administrator at the National Heart, Lung, and Blood Institute (NHLBI), where he oversaw a portfolio of clinical and translational studies, including single and multisite clinical trials, and large observational studies.

Prior to his tenure at NIH, Cure was the LEAP (Laboratory for Entrepreneurial Achievement in Pediatrics) Scholar, focused on innovation, translational science, and entrepreneurship in pediatrics, at Children’s National Health System. He later became the Clinical Research Center scientific director at the Clinical and Translational Science Institute at Children’s National and assistant professor at the George Washington School of Medicine and Health Sciences.

Cure received his M.D. from the Universidad del Norte in Barranquilla, Colombia, and his M.P.H. from the George Washington University. He conducted his postdoctoral fellow research in the Clinical Islet Transplant Program at the University of Miami Leonard M. Miller School of Medicine’s Diabetes Research Institute.

Professional Interests

Cure’s professional interests include clinical study design, start-up and implementation; large database analyses; electronic health records research integration; rare diseases; and multicenter research networks.

Selected Publications

  1. Validation of Cross-Sectional Studies with Longitudinal Meta-Analysis
  2. Adolescent BMI and Risk of Diabetes Versus Coronary Disease
  3. "Creating Hope" and Other Incentives for Drug Development for Children
  4. Current Challenges in Islet Transplantation
  5. Improved Metabolic Control and Quality of Life in Seven Patients with Type 1 Diabetes Following Islet after Kidney Transplantation